If you search for dendritic cell therapy in China, you will find clinics promising it. You will find far less about the rules that govern it. This page is about the rules.
The short answer: dendritic cell (DC) therapy is not available as routine clinical care anywhere in mainland China. It exists in two legal forms only — registered clinical trials, and a narrow, tightly regulated pathway inside the Hainan Boao Lecheng pilot zone. Anything sold to you outside those two routes is outside the framework.
That is not a reason to give up on the question. It is a reason to ask it precisely.
What dendritic cell therapy actually is
Dendritic cells are the immune system's antigen-presenting cells. They do not attack tumours themselves; they show tumour antigens to T cells and trigger the response that does. DC therapy — sometimes called a "DC vaccine" — takes a patient's own cells, matures them outside the body, loads them with tumour antigens, and returns them, with the aim of training the immune system against that specific cancer.
It is genuinely different from CAR-T. CAR-T engineers T cells to hit one defined target; China has approved seven CAR-T products, including the world's first solid-tumour CAR-T. DC therapy works upstream of that, on the immune system's own recognition step. One DC-based product has been approved anywhere — for prostate cancer in the United States in 2010 — and for most solid tumours DC therapy remains investigational, anywhere in the world, not only in China.
Why it is restricted in China
China was once the opposite of restrictive. Before 2016, cellular immunotherapy — DC, CIK, NK and others — was widely offered as a paid clinical service, with little regulatory oversight. A widely publicised 2016 case involving an unproven cellular treatment changed that overnight: the national health authority halted cellular immunotherapy as a clinical service across the country.
Since then, the only legitimate routes have been registered clinical trials, or — from 2019 — the special framework inside the Hainan Boao Lecheng pilot zone.
This matters because the popular impression runs the other way. People assume China is the place where you can simply buy the therapy that is not yet approved at home. For cellular therapy specifically, the opposite is true: China regulated it harder and earlier than most countries, and it has been tightening since.
The only two legal routes in 2026
1. Registered clinical trials. DC-based trials run at Chinese academic centres. Participation is normally funded by the trial, so the patient mainly covers travel and living costs — but eligibility is set by the protocol, admission is not guaranteed, and a trial is a research study, not a purchased treatment.
2. The Lecheng biomedical new-technology pathway. The Boao Lecheng pilot zone on Hainan is the only place in mainland China where cellular and gene therapies can be applied clinically outside a standard drug registration. It is not a loophole: projects must be approved, and treatment is restricted to approved protocols with defined eligibility. As of April 2026, 29 biomedical new-technology projects had been approved in the zone — across all technologies, not DC alone.
What changed in 2026 — read this before considering cellular therapy
Two national regulations took effect in May 2026: the Regulations on the Administration of Clinical Research and Clinical Translation of New Biomedical Technologies (effective 1 May 2026) and the revised Implementation Regulations of the Drug Administration Law (effective 15 May 2026). Together they formalise two tracks — a technology track for new biomedical techniques, and a drug track for registration — and for the first time set out how projects are stopped, not only how they are approved.
In September 2026 the zone published draft rules on suspending and withdrawing translation projects, open for public comment from 8–18 September. They define four outcomes — voluntary suspension, time-limited suspension, voluntary withdrawal, and mandatory withdrawal — and list eleven red lines that trigger mandatory withdrawal, including major safety defects, failure to correct identified problems, falsified data used to obtain approval, and unauthorised expansion of indications or patient groups. A department subject to mandatory withdrawal is barred from new projects for a year.
The direction of travel is clear: stricter entry, and a real exit mechanism where none existed before. For a patient, this is good news. It means the programmes still operating are the ones under scrutiny — and the ones that vanish under it were the ones you did not want.
What it costs
There is no public price list, and anyone who quotes you a fixed package for DC therapy should be treated carefully.
- Inside a registered trial, the therapy itself is normally funded by the study. Your costs are travel, accommodation and living expenses for the treatment period.
- Inside the Lecheng framework, the hospital quotes per case, based on your pathology, your prior treatment, and the specific approved protocol. It is not a menu item.
Neither route becomes cheaper because someone promised you an outcome. A fixed price attached to a guaranteed result is one of the clearest warning signs in this field.
What DC therapy can and cannot do
This is the part that most pages about DC therapy leave out.
Availability and benefit are two different things. DC therapy is a real area of research, run by serious people at serious hospitals. It may benefit some patients, in some conditions, under some protocols. But it is not an established cure for advanced solid tumours, and no honest doctor can promise you that it will make you cancer-free.
If your situation has brought you to this question, the useful version of it is not "can I buy DC therapy in China?" — it is "is there a registered trial or an approved project that my pathology actually qualifies for, and what does the evidence say about it?" Those two questions have different answers, and only one of them can be answered honestly by someone who is not selling you anything.
Warning signs
- A fixed package price attached to a promised outcome — especially anything described as a cure.
- A provider who cannot tell you which specific approved project or permit covers your treatment. If it cannot be named, it does not exist.
- Claims that "any major hospital in China can do this". They cannot; that is not how the framework works.
- Pressure to pay before you have anything in writing.
- Vagueness about where the treatment would be delivered. Under the current rules, cellular therapy in the mainland is confined to a small number of approved settings — not available on request in Beijing, Shanghai or Chengdu.
How to start
Ask three questions, and ask for the answers in writing:
- Which specific registered trial, or which approved Lecheng project, would cover my case?
- Does my pathology — my tumour type, my mutation status, my prior treatment — meet its eligibility criteria?
- Who is the responsible clinician, and can I have the assessment in writing?
If those three cannot be answered, you are not being offered a treatment. You are being offered a promise.
Our position: we coordinate and we ask questions; we do not sell treatment, and we do not sell hope. If your question is whether a cellular therapy route exists for your case, that is a question worth putting to the hospitals directly — and it is one we can help you put to them.